Atjaunināt sīkdatņu piekrišanu

E-grāmata: Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside

Edited by (Professor, Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD, USA)
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 156,48 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Molecular Basis of Neuropsychiatric Disorders: from Bench to BedsidePalielināt
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Progress in Molecular Biology and Translational Science, Volume 167, provides the most topical, informative and exciting monographs available on a wide variety of research topics related to Models and Biological Targets in Drug Discovery for Attention Deficit Hyperactivity Disorder, Novel Targets for Parkinson-Depression Co-morbidity. Utility of Cannabidiol (CBD) in Neuropsychiatric Disorders: A Short Review of the Recent Pre-clinical and Clinical Findings, The Many Sides of Microglia in Alcohol Use Disorders, Stress, Anxiety, Molecular Targets and More, Calcineurin Signaling in Psychiatric Disorders, Emerging Evidence for the Role of Pituitary Adenylate Cyclase- Activating Peptide (PACAP) in Neuropsychiatric Disorders, and more.

  • Includes comprehensive coverage of molecular biology
  • Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
  • Contains contributions from renowned experts in the field
Contributors ix
Preface xiii
1 Novel targets for parkinsonism-depression comorbidity
1(24)
Yousef Tizabi
Bruk Getachew
Antonei B. Csoka
Kebreten F. Manaye
Robert L. Copeland
1 Introduction
2(1)
2 Parkinson's disease
2(3)
3 Depression
5(2)
4 Co-morbid PD and depression
7(1)
5 Novel targets and/or drugs based on empirical evidence
8(4)
6 Concluding remarks and future direction
12(1)
Acknowledgment
12(1)
Disclaimers
13(1)
Financial disclosure/conflict of interest
13(1)
References
13(12)
2 Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings
25(52)
Sonja Elsaid
Stefan Kloiber
Bernard Le Foil
1 Introduction
26(2)
2 Pharmacology of cannabidiol
28(4)
3 Neurological disorders
32(13)
4 Psychiatric disorders
45(20)
5 Conclusions
65(2)
References
67(10)
3 Stress, psychiatric disorders, molecular targets, and more
77(30)
Fatin Atrooz
Hesong Liu
Samina Salim
1 Introduction
78(1)
2 Early life stress
79(1)
3 Early life stress and brain development
80(2)
4 Early life stress and the hypothalamic-pituitary-adrenal (HPA) axis
82(4)
5 Early life stress, epigenetic and genetic factors
86(3)
6 Early life stress and the immune system
89(2)
7 Oxidative stress and oxido-inflammation theory of stress
91(3)
8 Potential drug targets
94(1)
9 Conclusion
95(1)
Disclosure of interest
95(1)
References
95(12)
4 Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease
107(18)
Ramsha Shams
Naren L. Banik
Azizul Haque
1 Introduction
108(3)
2 Calpain
111(2)
3 ot-Synuclein
113(1)
4 Microglial activation, neuroinflammation, and neurodegeneration in PD
114(2)
5 T cell activation, neuroinflammation, and neurodegeneration in PD
116(1)
6 Calpain cleavage of a-synuclein and presentation by microglia and professional APCs
117(1)
7 Cross presentation of synuclein peptides to T cells
118(2)
8 Conclusions
120(1)
Acknowledgments
120(1)
Conflicts of interest
120(1)
References
121(4)
5 Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders
125(18)
Patrick J. Ronan
Sarah A. Flynn
Thomas P. Beresford
1 Introduction
126(1)
2 Calcineurin
126(1)
3 Alcohol and neuroinflammation
127(2)
4 Calcineurin and extended brain reward pathways
129(1)
5 Alcohol, calcineurin, and corticotropin releasing factor
129(1)
6 Calcineurin and reward signaling
130(1)
7 Corticotropin releasing factor, ethanol and neuroimmune processes
131(1)
8 Calcineurin signaling in other neuroinflammatory disorders
131(2)
9 Traumatic brain injury and alcohol abuse
133(1)
10 Traumatic brain injury and neuroinflammation
134(1)
11 Stress and neuroinflammation
134(1)
12 Genetic approach to understanding calcineurin function
135(1)
13 Conclusions
136(1)
Acknowledgments
137(1)
References
137(6)
6 Emerging evidence for the role of pituitary adenylate cyclase-activating peptide in neuropsychiatric disorders
143(16)
Kabirullah Lutfy
Gollapudi Shankar
1 Introduction
144(1)
2 PACAP and stress response
145(2)
3 PACAP and anxiety disorders
147(1)
4 PACAP and major depression
148(2)
5 PACAP and post-traumatic stress disorder (PTSD)
150(2)
6 PACAP and schizophrenia
152(1)
7 Concluding remarks
153(1)
Acknowledgment
154(1)
References
154(5)
7 Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities
159(20)
Shafiqur Rahman
Sami Alzarea
1 Introduction
160(1)
2 Astroglial dysfunction and major depressive disorder
161(1)
3 Microglial dysfunction and major depressive disorder
162(4)
4 Microglial nicotinic cholinergic mechanisms and major depressive disorder
166(5)
5 Conclusions
171(1)
Acknowledgments
172(1)
References
172(6)
Further reading
178(1)
8 Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disorders
179(44)
Jennifer K. Melbourne
K. Ryan Thompson
Hui Peng
Kimberly Nixon
1 Introduction
180(1)
2 Alcohol use disorders
180(2)
3 Alcohol-induced neuropathology
182(2)
4 Microglia
184(5)
5 Neuroimmune activation in AUDs
189(5)
6 The role of microglia in neuroimmune effects of alcohol
194(6)
7 Anti-inflammatory approaches as potential drug targets for AUDs
200(6)
8 Conclusion
206(1)
References
207(16)
9 Microglia as possible therapeutic targets for autism spectrum disorders
223(24)
Megumi Andoh
Yuji Ikegaya
Ryuta Koyama
1 Introduction
224(2)
2 Therapeutic targets for ASD treatment and possible involvement of microglia
226(7)
3 Synaptic deficits in ASDs
233(3)
4 Physical exercise, possibly a potent therapeutic strategy for ASDs
236(2)
5 Concluding remarks
238(1)
Acknowledgment
238(1)
References
239(8)
Index 247
Shafiqur Rahman, Ph.D. is Professor of Pharmacology in the Department of Pharmaceutical Sciences at South Dakota State University (SDSU) in Brookings, USA. He received his Ph.D. in Neuropharmacology from the Memorial University of Newfoundland, Canada. Dr. Rahman completed his post-doctoral fellowship in the Department of Psychiatry from Indiana University School of Medicine in Indianapolis in USA. Prior to joining SDSU, he worked as research scientist and faculty at the University of Kentucky in Lexington, USA and the University of Toronto, Canada. Dr. Rahman's research focus is drug discovery in neuropharmacology, i.e. the development of novel therapeutic candidates for the treatment of alcohol/nicotine addiction and neuropsychiatric disorders using animal models. His research resulted in over 200 publications/presentations, including peer-reviewed scientific articles, reviews, book chapters, meeting abstracts and seminar presentations. Dr. Rahman served on numerous scientific review panels and editorial boards of several scientific Journals. He has authored or edited multiple books or Journals in drug addiction and neuropharmacology field. Dr. Rahman is also affiliated with a number of professional organizations, including Society for Neuroscience and American Society for Pharmacology and Experimental Therapeutics.
Biežāk uzdotie jautājumi par e-grāmatām Biežāk uzdotie jautājumi par e-grāmatām
Permanent link: https://www.kriso.lv/db/97801281885692e.html
Keywords: